Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
MOVe-AHEAD
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) in Adults Residing With a Person With COVID-19
5 other identifiers
interventional
2,441
23 countries
226
Brief Summary
The purpose of the study is to assess if the study medication (molnupiravir, MK-4482) will prevent symptomatic coronavirus disease 2019 (COVID-19) in adults who live with someone with confirmed COVID-19 infection. This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study; half of the study participants will receive molnupiravir twice daily by mouth and the other half will receive a placebo. The primary objectives of the study are to determine if molnupiravir prevents symptomatic COVID-19 disease and to evaluate its safety and tolerability. All participants who develop COVID-19 during the study are still eligible for any COVID-19 treatment recommended by their doctor.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Aug 2021
Shorter than P25 for phase_3
226 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 24, 2021
CompletedFirst Posted
Study publicly available on registry
June 25, 2021
CompletedStudy Start
First participant enrolled
August 11, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 16, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
November 16, 2022
CompletedResults Posted
Study results publicly available
February 6, 2024
CompletedSeptember 26, 2024
September 1, 2024
1.3 years
June 24, 2021
November 6, 2023
September 10, 2024
Conditions
Outcome Measures
Primary Outcomes (3)
Percentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline Nasopharyngeal (NP) Swabs and Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With Symptoms) Through Day 14
Percentage of participants who had undetectable SARS-CoV-2 in baseline NP swabs and developed COVID-19 (laboratory-confirmed SARS-CoV-2 infection with symptoms) through Day 14 were reported.
Day 14
Percentage of Participants With ≥1 Adverse Event
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
29 days
Percentage of Participants Discontinuing From Study Therapy Due to AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Up to 5 days
Secondary Outcomes (4)
Percentage of Participants (Regardless of SARS-CoV-2 in Baseline NP Swabs) Who Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With Symptoms) Through Day 14
Up to Day 14
Percentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline NP Swabs and Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With Symptoms) Through Day 29
Up to Day 29
Percentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline NP Swabs and Developed Detectable SARS-CoV-2 in NP Swabs on or Before Day 14
Up to Day 14
Percentage of Participants Who Had Detectable SARS-CoV-2 in Baseline NP Swabs and Developed COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) Through Day 14
Up to Day 14
Study Arms (2)
Molnupiravir
EXPERIMENTALParticipants take molnupiravir 800 mg every 12 hours (Q12H) on Days 1 to 5.
Placebo
PLACEBO COMPARATORParticipants take placebo Q12H on Days 1 to 5.
Interventions
Eligibility Criteria
You may qualify if:
- Lives in a household with an index case where the index case is a person with documented COVID-19 (laboratory-confirmed SARS-CoV-2 infection with symptoms case) and must have 1) a first detectable SARS-CoV-2 test result from a sample collected within ≤5 days prior to randomization of the participant, and 2) at least 1 symptom attributable to COVID-19 (e.g., fever, difficulty breathing)
- Does not have confirmed or suspected COVID-19
- Is willing and able to take oral medication
- For males, agrees to be abstinent from penile-vaginal intercourse OR agrees to use a highly effective contraceptive method while receiving study drug and for ≥3 months after the last dose of study drug
- Is female and not pregnant/breastfeeding and at least one of the following applies during the study and for ≥4 days after: is not a woman of childbearing potential (WOCBP), is a WOCBP and uses highly effective contraception (low user dependency method OR a user dependent hormonal method in combination with a barrier method), or is a WOCBP who is abstinent from heterosexual intercourse
You may not qualify if:
- Has a prior history of laboratory-confirmed SARS-CoV-2 infection (with or without symptoms) within 6 months prior to randomization
- Has either of the following: human immunodeficiency virus (HIV) with a recent viral load \>50 copies/mL (regardless of CD4 count) or an acquired immunodeficiency syndrome (AIDS)-defining illness
- Has a history of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection with any of the following: cirrhosis, end-stage liver disease, hepatocellular carcinoma; aspartate transaminase (AST) and/or (ALT) \>3x upper limit of normal at screening
- Has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator
- Has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to participants with conditions that could limit gastrointestinal absorption of capsule contents
- Has received, is taking, or is anticipated to require any prohibited therapies
- Has received a COVID-19 vaccination with the first dose ≥7 days prior to randomization
- Is unwilling to abstain from participating in another interventional clinical study through Day 29 with an investigational compound or device, including those for COVID-19 therapeutics
- Is living in a household with \>10 people
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (226)
Cahaba Research, Inc. ( Site 2523)
Birmingham, Alabama, 35235, United States
The Institute for Liver Health DBA Arizona Clinical Trials ( Site 2484)
Mesa, Arizona, 85210, United States
The Institute for Liver Health DBA Arizona Clinical Trials ( Site 2448)
Tucson, Arizona, 85712, United States
Hope Clinical Research ( Site 2400)
Canoga Park, California, 91303, United States
Carbon Health ( Site 2515)
Carlsbad, California, 92009, United States
UCSF Fresno ( Site 2528)
Fresno, California, 93701, United States
ASCADA Research, LLC ( Site 2516)
Fullerton, California, 92835, United States
Marvel Clinical Research ( Site 2490)
Huntington Beach, California, 92647, United States
National Research Institute ( Site 2452)
Los Angeles, California, 90057, United States
Valley Clinical Trials Inc. ( Site 2406)
Northridge, California, 91325, United States
Carbon Health ( Site 2514)
Oakland, California, 94610, United States
University of California Davis ( Site 2497)
Sacramento, California, 95817, United States
Millennium Clinical Trials ( Site 2468)
Simi Valley, California, 93065, United States
Future Innovative Treatments, LLC ( Site 2471)
Colorado Springs, Colorado, 80907, United States
Emerson Clinical Research Institute ( Site 2457)
Washington D.C., District of Columbia, 20011, United States
Synergy Healthcare ( Site 2521)
Bradenton, Florida, 34208, United States
Accel Research Sites-DeLand Clinical Research Unit ( Site 2535)
DeLand, Florida, 32720, United States
Velocity Clinical Research, Hallandale Beach ( Site 2485)
Hallandale, Florida, 33009, United States
Indago Research and Health Center Inc ( Site 2412)
Hialeah, Florida, 33012, United States
Advanced Research For Health Improvement LLC ( Site 2436)
Immokalee, Florida, 34142, United States
Clinical Site Partners, LLC d/b/a CSP Miami ( Site 2508)
Miami, Florida, 33186, United States
CDC Research Institute, LLC ( Site 2540)
Port Saint Lucie, Florida, 34952, United States
Clinical Research Trials of Florida ( Site 2402)
Tampa, Florida, 33607, United States
Clinical Site Partners, LLC d/b/a CSP Miami ( Site 2425)
Winter Park, Florida, 32789, United States
Balanced Life Healthcare Solutions/SKYCRNG ( Site 2539)
Lawrenceville, Georgia, 30046, United States
Chicago Clinical Research Institute Inc ( Site 2454)
Chicago, Illinois, 60607, United States
Rush University Medical Center ( Site 2510)
Chicago, Illinois, 60612, United States
Southern Clinical Research Associates ( Site 2542)
Metairie, Louisiana, 70001, United States
MedPharmics, LLC ( Site 2443)
Metairie, Louisiana, 70006, United States
Institute of Human Virology ( Site 2504)
Baltimore, Maryland, 21201, United States
Centennial Medical Group ( Site 2435)
Elkridge, Maryland, 21075, United States
Jadestone Clinical Research, LLC ( Site 2530)
Silver Spring, Maryland, 20904, United States
Michigan Center of Medical Research ( Site 2445)
Farmington Hills, Michigan, 48334, United States
Michigan Center of Medical Research ( Site 2525)
Lathrup Village, Michigan, 48076, United States
Allina Health Infectious Diseases Research Clinic ( Site 2507)
Minneapolis, Minnesota, 55404, United States
Prime Health and Wellness/SKYCRNG ( Site 2538)
Fayette, Mississippi, 39069, United States
Quinn Healthcare/Skycrng ( Site 2537)
Ridgeland, Mississippi, 39157, United States
University of Missouri Hospital ( Site 2486)
Columbia, Missouri, 65201, United States
Mercury Street Medical Group PLLC ( Site 2476)
Butte, Montana, 59701, United States
University of Nebraska Medical Center ( Site 2430)
Omaha, Nebraska, 68198-3135, United States
Excel Clinical Research, LLC ( Site 2404)
Las Vegas, Nevada, 89109, United States
ID Care ( Site 2466)
Hillsborough, New Jersey, 08844, United States
Amici Clinical Research LLC ( Site 2426)
Raritan, New Jersey, 08869, United States
AXCES Research Group ( Site 2437)
Santa Fe, New Mexico, 87505, United States
Montefiore Medical Center ( Site 2503)
The Bronx, New York, 10462, United States
ECU Adult Specialty Care ( Site 2415)
Greenville, North Carolina, 27834, United States
The Lindner Center for Research and Education at The Christ Hospital ( Site 2517)
Cincinnati, Ohio, 45219, United States
Dayton Clinical Research ( Site 2488)
Dayton, Ohio, 45406, United States
Cherokee Nation WW Hastings Indian Hospital/Cherokee Nation Health Services ( Site 2459)
Tahlequah, Oklahoma, 74464, United States
Preferred Clinical Research ( Site 2470)
Pittsburgh, Pennsylvania, 15236, United States
Velocity Clinical Research-Providence ( Site 2432)
East Greenwich, Rhode Island, 02818, United States
Tribe Clinical Research, LLC ( Site 2409)
Greenville, South Carolina, 29607, United States
PharmaTex Research, LLC ( Site 2541)
Amarillo, Texas, 79109, United States
TTS Research ( Site 2433)
Boerne, Texas, 78006, United States
Houston Methodist Hospital ( Site 2463)
Houston, Texas, 77030, United States
Santa Clara Family Clinic ( Site 2462)
Houston, Texas, 77087, United States
Crossroads Clinical Research LLC ( Site 2451)
Victoria, Texas, 77901, United States
TPMG Clinical Research ( Site 2495)
Williamsburg, Virginia, 23188, United States
Covid-19 Clinical Research Center (CCRC) ( Site 2421)
Seattle, Washington, 98109, United States
Sanatorio de la Trinidad Mitre ( Site 0108)
CABA, Buenos Aires, C1039AAO, Argentina
Mautalen Salud e Investigacion ( Site 0103)
Caba, Buenos Aires, C1128AAF, Argentina
Hospital Italiano de Buenos Aires ( Site 0102)
CABA, Buenos Aires, C1199ABB, Argentina
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0105)
Mar del Plata, Buenos Aires, B7600FZO, Argentina
Clinica Independencia ( Site 0104)
Munro, Buenos Aires, B1605FRE, Argentina
Grupo Oroño Centro medico San Nicolas ( Site 0109)
San Nicolás de los Arroyos, Buenos Aires, B2900DPA, Argentina
Instituto Medico de la Fundacion Estudios Clinicos ( Site 0106)
Rosario, Santa Fe Province, 2000, Argentina
CEMIC ( Site 0101)
Buenos Aires, C1431FWO, Argentina
Fundaçao de Medicina Tropical Doutor Heitor Vieira Dourado ( Site 0303)
Manaus, Amazonas, 69040-000, Brazil
Faculdade de Medicina da Universidade Federal de Mato Grosso do Sul - UFMS ( Site 0305)
Campo Grande, Mato Grosso do Sul, 79070-900, Brazil
Hospital Nossa Senhora das Gracas ( Site 0310)
Curitiba, Paraná, 80810-040, Brazil
Oncosite-Centro de Pesquisa Clinica em Oncologia ( Site 0300)
Ijuí, Rio Grande do Sul, 98700-000, Brazil
Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0312)
São José do Rio Preto, São Paulo, 15090000, Brazil
Centro de Referencia Professor Helio Fraga - FIOCRUZ/RJ ( Site 0314)
Rio de Janeiro, 22780-192, Brazil
Centro de Referência e Treinamento DST/AIDS ( Site 0301)
São Paulo, 04121-000, Brazil
Medical Center Hera EOOD ( Site 3001)
Sofia, Sofia (stolitsa), 1510, Bulgaria
Medical Center Hera Kyustendi EOOD ( Site 3003)
Kyustendil, 2500, Bulgaria
Medical Center Hera EOOD - Montana branch ( Site 3002)
Montana, 3400, Bulgaria
Fundacion Centro de Investigacion Clinica CIC ( Site 0402)
Medellín, Antioquia, 050021, Colombia
Centro Cientifico Asistencial Jose Luis Accini ( Site 0412)
Barranquilla, Atlántico, 080020, Colombia
Clinica de la Costa Ltda. ( Site 0407)
Barranquilla, Atlántico, 080020, Colombia
Caja de Compensacion Familiar CAFAM ( Site 0403)
Bogotá, Bogota D.C., 111211, Colombia
Hospital Universitario Clinica San Rafael ( Site 0410)
Bogota, Cundinamarca, 110411, Colombia
Healthy Medical Center S.A.S ( Site 0413)
Zipaquirá, Cundinamarca, 250252, Colombia
Oncomedica S.A. ( Site 0406)
Montería, Departamento de Córdoba, 230002, Colombia
Fundacion Centro de Investigaciones Clinicas CARDIOMET ( Site 0409)
Pereira, Risaralda Department, 660003, Colombia
Instituto Neumologico del Oriente S.A. ( Site 0408)
Bucaramanga, Santander Department, 681004, Colombia
Fundacion Valle del Lili ( Site 0405)
Cali, Valle del Cauca Department, 760032, Colombia
Unidad de Aislamiento del Centro de Obstetricia y Ginecologia ( Site 2650)
Santo Domingo, Nacional, 10605, Dominican Republic
Masri - CRC - Ain Shams University ( Site 2900)
Cairo, Cairo Governorate, 11566, Egypt
Masri - CRC - Ain Shams University ( Site 2910)
Cairo, Cairo Governorate, 11566, Egypt
National Hepatology and Tropical Medicine Research Institute ( Site 2930)
Cairo, Cairo Governorate, 11796, Egypt
Air Force Specialized Hospital Clinical Research Center ( Site 2920)
Cairo, Cairo Governorate, 11835, Egypt
National Center for allergies and chest ( Site 2940)
Giza, Giza Governorate, 12651, Egypt
Imbaba Fevers Hospital ( Site 2945)
Giza, Giza Governorate, 12661, Egypt
Maison de Sante Universitaire La Providence ( Site 0506)
Toulouse, Haute-Garonne, 31500, France
CHU de la Reunion - Groupe Hospitalier Sud ( Site 0508)
Saint-Pierre, La Reunion, 97448, France
CHU Martinique ( Site 0511)
Fort-de-France, Martinique, 97200, France
Maison de santé du Pays Neufchatelois ( Site 0507)
Neufchâtel-en-Bray, Seine-Maritime, 76270, France
Hôpital Pitié - Salpêtrière ( Site 0501)
Paris, Île-de-France Region, 75013, France
Centro de Investigaciones Pediatricas ( Site 0703)
Guatemala City, 01001, Guatemala
Unidad de Diagnostico Cardiologico ( Site 0701)
Guatemala City, 01001, Guatemala
Clínica Médica Especializada en Pediatría e Infectología Pediátrica - Dr. Mario Melgar ( Site 0702)
Guatemala City, 01009, Guatemala
Clinica Privada ( Site 0705)
Guatemala City, 01010, Guatemala
Private Clinic - Dr. Hugo Pezzarossi ( Site 0704)
Guatemala City, 01015, Guatemala
LONA MEDIC Kft ( Site 0804)
Orosháza, Bekes County, 5900, Hungary
Debreceni Egyetem Klinikai Kozpont- Infektologiai Klinika ( Site 0824)
Debrecen, Hajdú-Bihar, 4031, Hungary
Bugat Pal Korhaz ( Site 0817)
Gyöngyös, Heves County, 3200, Hungary
Medifarma-98 Kft. ( Site 0808)
Nyíregyháza, Szabolcs-Szatmár-Bereg, 4400, Hungary
DRC Gyogyszervizsgalo Kozpont Kft. ( Site 0801)
Balatonfüred, Veszprém megye, 8230, Hungary
Obudai Egeszsegugyi Centrum - OEC ( Site 0821)
Budapest, 1036, Hungary
Strazsahegy Medicina Bt ( Site 0823)
Budapest, 1171, Hungary
Obudai Egeszsegugyi Centrum - Zalaegerszeg ( Site 0819)
Zalaegerszeg, 8900, Hungary
IUHW Narita Hospital ( Site 1105)
Narita, Chiba, 286-8520, Japan
National Hospital Organization Okinawa National Hospital ( Site 1109)
Ginowan, Okinawa, 901-2214, Japan
Social Medical Corporation Yuuaikai Yuuai Medical Center ( Site 1108)
Tomigusuku, Okinawa, 901-0224, Japan
Chiba Aoba Municipal Hospital ( Site 1100)
Chiba, 260-0852, Japan
Global Healthcare Clinic ( Site 1106)
Tokyo, 102-0083, Japan
Den-en-chofu family clinic ( Site 1104)
Tokyo, 145-0071, Japan
Center Hospital of the National Center for Global Health and Medicine ( Site 1101)
Tokyo, 162-8655, Japan
Sekino Hospital ( Site 1110)
Tokyo, 171-0014, Japan
Center for Clinical Research (CCR) KEMRI ( Site 1929)
Nairobi, Nairobi City, 00200, Kenya
Partners in Health Research and Development PHRD ( Site 1928)
Nairobi, Nairobi City, 00202, Kenya
KEMRI-CMR-RCTP- Kenya Medical Research Institute Kisumu ( Site 1925)
Kisumu, 40100, Kenya
Hospital Raja Perempuan Zainab II ( Site 2851)
Kota Bharu, Kelantan, 15586, Malaysia
Klinik Kesihatan Masjid Tanah ( Site 2850)
Masjid Tanah, Melaka, 78300, Malaysia
Morales Vargas Centro de Investigacion, S.C. ( Site 1318)
León, Guanajuato, 37000, Mexico
Hospital General de Acapulco ( Site 1319)
Acapulco de Juárez, Guerrero, 39570, Mexico
Instituto Jalisciense de Metabolismo SC ( Site 1314)
Guadalajara, Jalisco, 44670, Mexico
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran ( Site 1308)
Mexico City, Mexico City, 14080, Mexico
Centro Médico Universitario ( Site 1316)
Cuernavaca, Morelos, 62210, Mexico
CHRISTUS - LATAM HUB CENTER OF EXCELLENCE AND INNOVATION S.C. ( Site 1315)
General Escobedo, Nuevo León, 66055, Mexico
Centro de Investigacion y Avances Medicos Especializados -CIAME ( Site 1301)
Cancún, Quintana Roo, 77500, Mexico
Köhler & Milstein Research S.A. de C.V. ( Site 1300)
Mérida, Yucatán, 97070, Mexico
Centro de Investigacion Medica Aguascalientes ( Site 1305)
Aguascalientes, 20116, Mexico
ICARO Investigaciones en Medicina ( Site 1313)
Chihuahua City, 31000, Mexico
Medica Sur S.A.B de C.V. ( Site 1303)
Mexico City, 14050, Mexico
Oaxaca Site Management Organization S.C. ( Site 1304)
Oaxaca City, 68000, Mexico
Arké SMO S.A de C.V ( Site 1306)
Veracruz, 91910, Mexico
Policlínico Especializado en Neurología - Unid. Inv. Neurológica ( Site 1403)
La Perla, Qallaw, 07011, Peru
Clínica Ricardo Palma ( Site 1406)
Lima, 15036, Peru
Asociacion Civil por la Salud ( Site 1411)
Lima, 15046, Peru
Investigaciones Medicas en Salud - INMENSA ( Site 1401)
Lima, 15046, Peru
Asociacion Civil IMPACTA Salud y Educacion - Sede San Miguel ( Site 1410)
Lima, 15088, Peru
Clinica Providencia ( Site 1400)
Lima, 15088, Peru
Instituto de Investigacion Nutricional - Anexo Huascar ( Site 1404)
Lima, 15423, Peru
Asian Hospital and Medical Center ( Site 1503)
Muntinlupa, National Capital Region, 1780, Philippines
Quirino Memorial Medical Center ( Site 1501)
Quezon City, National Capital Region, 1109, Philippines
Health Index Multi-Specialty and Lying -in Clinic ( Site 1504)
Cavite, 4102, Philippines
Centrul Medical Unirea SRL ( Site 1707)
Cluj-Napoca, Cluj, 400349, Romania
S.C Materna Care SRL ( Site 1702)
Timișoara, Timiș County, 300645, Romania
Centrul Medical Unirea ( Site 1705)
Brasov, 500091, Romania
Centrul Medical Unirea SRL Bucuresti ( Site 1706)
Bucharest, 011601, Romania
Delta Heath Care S.R.L ( Site 1708)
Bucharest, 014142, Romania
SC Policlinica CCBR SRL. Bucuresti ( Site 1704)
Bucharest, 030463, Romania
Centrul Medical Unirea SRL Constanta ( Site 1703)
Constanța, 900540, Romania
Centrul Medical Unirea SRL IASI ( Site 1701)
Iași, 700023, Romania
FSBI Central Hospital with Policlinics ( Site 1807)
Moscow, Moscow, 121359, Russia
Infectious Clinical Hospital # 1 ( Site 1834)
Moscow, Moscow, 125310, Russia
SPb SBHI. City outpatient clinic No.44 ( Site 1830)
Saint Petersburg, Sankt-Peterburg, 192071, Russia
SPb SBHI City outpatient clinic 112 ( Site 1829)
Saint Petersburg, Sankt-Peterburg, 195427, Russia
Medical Research Institute LLC. ( Site 1814)
Saint Petersburg, Sankt-Peterburg, 196084, Russia
Limited liability company "Scientific research center Eco-safety" ( Site 1809)
Saint Petersburg, Sankt-Peterburg, 196143, Russia
Smorodintsev Research Institute of Influenza ( Site 1833)
Saint Petersburg, Sankt-Peterburg, 197376, Russia
City Polyclinic #88 ( Site 1808)
Saint Petersburg, Sankt-Peterburg, 198261, Russia
Nikolaevskaya hospital ( Site 1810)
Saint Petersburg, Sankt-Peterburg, 198510, Russia
SPb SBHI City outpatient clinic 4 ( Site 1831)
Saint Petersburg, Sankt-Peterburg, 199406, Russia
LLC -Medical Center . Capital-Polis ( Site 1825)
Saint-Petrsburg, Sankt-Peterburg, 190013, Russia
St.Petersburg Outpatient Clinic No. 109 ( Site 1818)
Saint-Petrsburg, Sankt-Peterburg, 192289, Russia
Smolensk State Medical Academy ( Site 1803)
Smolensk, Smolensk Oblast, 214019, Russia
Republican Clinical Infectious Hospital n.a. A.F. Agafonov ( Site 1802)
Kazan', Tatarstan, Respublika, 420140, Russia
Voronezh Regional Clinical Hospital #1 ( Site 1823)
Voronezh, Voronezskaja Oblast, 394066, Russia
LLC -Clinic of modern medicine of Doctor Bogorodskaya ( Site 1828)
Yaroslavl, Yaroslavl Oblast, 150001, Russia
IATROS International ( Site 1921)
Bloemfontein, Free State, 9300, South Africa
REIMED Reiger Park ( Site 1910)
Boksburg, Gauteng, 1459, South Africa
Midrand Medical Centre ( Site 1913)
Halfway House, Gauteng, 1685, South Africa
Wits Health Consortium. Clinical HIV Research Unit ( Site 1923)
Johannesburg, Gauteng, 2041, South Africa
Right To Care Research - Esizayo ( Site 1907)
Johannesburg, Gauteng, 2087, South Africa
DJW Navorsing ( Site 1915)
Krugersdorp, Gauteng, 1739, South Africa
Zinakekele Medical Centre ( Site 1926)
Moloto, Gauteng, 1022, South Africa
Mzansi Ethical Research Centre ( Site 1918)
Mpumalanga, Gauteng, 1055, South Africa
Global Clinical Trial Centre ( Site 1904)
Pretoria, Gauteng, 0186, South Africa
Jongaie Research ( Site 1900)
Pretoria West, Gauteng, 0183, South Africa
Dr Jugnundun & Partners ( Site 1905)
Durban, KwaZulu-Natal, 4091, South Africa
Enhancing Care Foundation-DICRS ( Site 1922)
Durban, KwaZulu-Natal, 4091, South Africa
Private Practice - Dr. Neyaseelan Gounden ( Site 1911)
Durban, KwaZulu-Natal, 4093, South Africa
Limpopo Clinical Research Initiative ( Site 1901)
Thabazimbi, Limpopo, 0380, South Africa
TASK Applied Science ( Site 1920)
Cape Town, Western Cape, 7405, South Africa
DTHF Masiphumelele Clinical Research Site ( Site 1919)
Cape Town, Western Cape, 7975, South Africa
Be Part Yoluntu Centre ( Site 1914)
Paarl, Western Cape, 7626, South Africa
Paarl Research Centre ( Site 1924)
Paarl, Western Cape, 7646, South Africa
Hospital Universitari Germans Trias i Pujol ( Site 2010)
Badalona, Barcelona, 08916, Spain
CAP Centelles ( Site 2011)
Centelles, Barcelona, 08540, Spain
Hospital de Alcorcon ( Site 2003)
Alcorcón, Madrid, Comunidad de, 28922, Spain
C.S. Vallcarca-Sant Gervasi ( Site 2000)
Barcelona, 08023, Spain
CAP de Sardenya ( Site 2009)
Barcelona, 08025, Spain
Hospital Universitario Infanta Leonor ( Site 2002)
Madrid, 28031, Spain
Hospital Universitario La Paz ( Site 2024)
Madrid, 28046, Spain
HIV-NAT AIDS Research Centre ( Site 2804)
Bangkok, Bangkok, 10330, Thailand
Chulabhorn Hospital ( Site 2801)
Lak Si, Bangkok, 10210, Thailand
Rajavithi Hospital ( Site 2803)
Ratchathewi, Bangkok, 10400, Thailand
The Golden Jubilee Medical Center ( Site 2800)
Phutthamonthon, Changwat Nakhon Pathom, 73170, Thailand
Songklanagarind Hospital ( Site 2802)
Hat Yai, Changwat Songkhla, 90110, Thailand
Atakent Acibadem Hastanesi ( Site 2103)
Halkali/K.cekmece, Istanbul, 34303, Turkey (Türkiye)
Ankara Universitesi Ibni Sina Hastanesi ( Site 2101)
Ankara, 06230, Turkey (Türkiye)
Hacettepe Universitesi Tip Fakultesi ( Site 2102)
Ankara, 06230, Turkey (Türkiye)
Gazi Universitesi Tip Fakultesi Hastanesi ( Site 2106)
Ankara, 06560, Turkey (Türkiye)
Ankara Sehir Hastanesi ( Site 2111)
Ankara, 06800, Turkey (Türkiye)
Istanbul Universitesi Istanbul Tip Fakultesi ( Site 2110)
Istanbul, 34093, Turkey (Türkiye)
Medipol Universite Hastanesi ( Site 2108)
Istanbul, 34214, Turkey (Türkiye)
Basaksehir Cam ve Sakura City Hospital ( Site 2112)
Istanbul, 34494, Turkey (Türkiye)
Sancaktepe Prof Dr Ilhan Varank EAH-Prof Dr Feriha Oz Hastanesi ( Site 2113)
Istanbul, 34785, Turkey (Türkiye)
Ege Universitesi Tip Fakultesi Hastanesi ( Site 2105)
Izmir, 35100, Turkey (Türkiye)
Sakarya Universitesi Egitim ve Arastirma Hastanesi ( Site 2107)
Sakarya, 54100, Turkey (Türkiye)
Ivano-Frankivsk Regional Clinical Infectious Diseases Hospital ( Site 2232)
Ivano-Frankivsk, Ivano-Frankivsk Oblast, 76007, Ukraine
Regional Phthisiopulmonological Center ( Site 2203)
Ivano-Frankivsk, Ivano-Frankivsk Oblast, 76018, Ukraine
NPME -Central Clinical Hospital of Ivano-Frankivsk City Council ( Site 2204)
Ivano-Frankivsk, Ivano-Frankivsk Oblast, 76025, Ukraine
Non profit municipal enterprise City hospital student of Kharkiv city council ( Site 2229)
Kharkiv, Kharkivs’ka Oblast’, 61002, Ukraine
PCNE Kharkiv City polyclinic 9 of the Kharkiv City Council ( Site 2201)
Kharkiv, Kharkivs’ka Oblast’, 61172, Ukraine
Limited Liability Company Medical center Healthy Happy ( Site 2225)
Kyiv, Kyivska Oblast, 01033, Ukraine
MNPE Consultative-Diagnostic Centre of Desnyanskyi District of Kyiv ( Site 2205)
Kyiv, Kyivska Oblast, 02232, Ukraine
Kyiv railway clinical hospital 2 of Branch Health center ( Site 2207)
Kyiv, Kyivska Oblast, 03049, Ukraine
Municipal Noncommercial Enterprise Lviv 4th City Clinical Hospital ( Site 2200)
Lviv, Lviv Oblast, 79011, Ukraine
Odesa Regional Center of Socially Significant Diseases ( Site 2230)
Odesa, Odesa Oblast, 65014, Ukraine
MNCE -Odesa regional clinical hospital of Odesa regional council ( Site 2226)
Odesa, Odesa Oblast, 65025, Ukraine
Municipal Enterprise Poltava Regional Clinical Infectious Hospital ( Site 2227)
Poltava, Poltava Oblast, 36011, Ukraine
Medical Clinical Investigational Center of Medical Center Health Clinic ( Site 2210)
Vinnytsia, Vinnytsia Oblast, 21009, Ukraine
Related Publications (1)
Alpizar SA, Accini J, Anderson DC, Eysa B, Medina-Pinon I, Ohmagari N, Ostrovskyy MM, Aggrey-Amable A, Beck K, Byrne D, Grayson S, Hwang PMT, Lonchar JD, Strizki J, Xu Y, Paschke A, De Anda CS, Sears PS; MOVe-AHEAD study group. Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial. J Infect. 2023 Nov;87(5):392-402. doi: 10.1016/j.jinf.2023.08.016. Epub 2023 Sep 9.
PMID: 37690669RESULT
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Senior Vice President, Global Clinical Development
- Organization
- Merck Sharp & Dohme LLC
Study Officials
- STUDY DIRECTOR
Medical Director
Merck Sharp & Dohme LLC
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 24, 2021
First Posted
June 25, 2021
Study Start
August 11, 2021
Primary Completion
November 16, 2022
Study Completion
November 16, 2022
Last Updated
September 26, 2024
Results First Posted
February 6, 2024
Record last verified: 2024-09
Data Sharing
- IPD Sharing
- Will share
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf